Subsequent Events

9 Months Ended

Sep. 30, 2013

Subsequent Events [Abstract]

Subsequent Events

11.      SUBSEQUENT EVENTS

In October 2013, following the Company’s announcement of the results of its Phase 3 trial of Allovectin^® and the subsequent decline of the price of its common stock, a complaint was filed, on behalf of certain purchasers of the Company’s common stock, in the U.S. District Court for the Southern District of California against the Company and certain of the Company’s current and former officers. The complaint includes claims asserted under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and has been brought as a purported shareholder class action. In general, the complaint alleges that the defendants violated the federal securities laws by making materially false and misleading statements regarding the Company’s business and prospects for Allovectin^®, thereby artificially inflating the price of the Company’s common stock. The plaintiff is seeking unspecified monetary damages and other relief. The Company plans to vigorously defend against the claims advanced.